Will the FDA approve Any psychedelic substance for medical use this year?
🗂 Part of event: Will the FDA approve any psychedelic substance for medical use this year? →💡 What the odds say
The market puts this at about a 42% chance — less likely than not.
No money — just record your call and see if you were right. Yes is at 42% right now.
The real story is that despite Trump's executive order in April 2026 to accelerate psychedelic access (Reuters, Apr 21), the FDA has not yet approved any psychedelic substance this year, and the market's 42% Yes reflects doubt that the agency will move fast enough before Jan 1, 2027.
📊 Base rate: Historically, the FDA approves about 20-30% of new molecular entities in a given year, but for novel psychedelic drugs, the prior is even lower due to limited clinical trial data and regulatory caution.
What's driving it
- • Trump's April 2026 executive order to accelerate psychedelic drug treatments (Reuters, Apr 21) gave a major boost to Yes odds, but the market has since settled as no approval has materialized.
- • A July 2026 CNBC report highlighting a 'big buy signal' in psychedelic stocks (CNBC, Jul 19) suggests renewed investor optimism, yet the FDA remains silent on any new approvals.
- • State-level pilots, such as Beacon Hill's embrace of psychedelic mental health treatments (Boston Globe, Jul 9), show growing institutional support but do not directly affect FDA's scientific review.
The case for YES
- • The Trump administration's explicit order to ease restrictions on psychedelics for PTSD (Reuters, Apr 17) and the subsequent interest in ibogaine (CNN, Apr 22) signal high-level political will to push for approval.
- • FDA has historically fast-tracked drugs for unmet mental health needs, and the executive order could pressure the agency to expedite a decision on a substance like MDMA or psilocybin before year-end.
- • The market is still below 50%, indicating that a positive surprise (e.g., a breakthrough therapy designation or approval) could materialize in the remaining months.
The case for NO
- • No FDA approval of any psychedelic has occurred as of late July 2026, and the agency's typical review cycle for new drugs takes well over a year, making a 2026 approval unlikely.
- • The executive order (Reuters, Apr 21) is not a legally binding mandate; it sets policy direction but does not override FDA's independent safety and efficacy standards.
- • Safety concerns about psychedelics, especially cardiovascular risks and psychological adverse events, may delay or prevent approval even with political support.
What to watch
- • Any announcement of an FDA advisory committee meeting for a psychedelic drug (likely positive direction if date set, as it indicates review progress).
- • Release of phase 3 trial results for a psychedelic candidate (positive direction if results are strong).
- • The November 2026 midterm elections could shift political priorities away from psychedelic deregulation if Republicans lose control (negative direction for Yes).
AI-generated · grounded in recent news + odds · informational only, not advice. Verify on the source platform.
Data from Kalshi’s public API, for informational purposes only. PredictPal is not affiliated with any platform and does not facilitate trading.
Discussion
Loading…
How it resolves
Settled by Kalshi, a CFTC-regulated US exchange, against the official source named in each contract (e.g. a government release or election certification), with an Outcome Review Committee as a backstop for disputes.
Resolution criteria
If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.
ⓘ A market settles under its own written rules, which can lag what looks decided in the news — so the price may not move to 100% the moment an outcome seems obvious.
View the official rules on Kalshi ↗Related markets
Apple Announces AI Glasses by September 30, 2026
2 outcomes
Will Anthropic release its next Mythos-class model to the public by August 31, 2026?
Yes ≈ 46% chance
Which of these Language Models will beat me at chess?
The field is extremely concentrated on 'any model announced before 2034' at 88%, but the long tail of 22 candidates above 5% suggests bettors see many plausible paths to a 1900-rated human being beaten by a future LLM, with the single biggest recent shift being the 2025-08-15 Business Insider report that OpenAI's o3 swept a chess tournament against xAI's Grok 4, likely boosting confidence in near-term AI chess ability.
52 outcomes